Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Burt, V. K. Articles by Stewart, D. E. Search for Related Content PubMed Citation Articles by Burt, V. K. Articles by Stewart, D. E. Gender Depression Antidepressants

Duloxetine for the Treatment of Major Depressive Disorder in Women Ages 40 to 55 Years

Received April 20, 2004; revision received Oct. 26, 2004; accepted Nov. 15, 2004. From the Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis; the Department of Psychiatry, Indiana University School of Medicine, Indianapolis; the Department of Psychiatry, McLean Hospital, Belmont, Mass.; the Department of Psychiatry, Harvard Medical School, Boston; and the University Health Network, University of Toronto, Ontario, Canada. Address correspondence and reprint requests to Dr. Wohlreich, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285; mwmd{at}lilly.com (e-mail).

The efficacy of duloxetine in the treatment of major depressive disorder in women of approximately perimenopausal age (40–55 years; 62 placebo subjects and 55 subjects taking duloxetine, 60 mg/day) was compared with that observed in cohorts of younger (<40 years, 94 placebo subjects and 85 duloxetine subjects) and older (>55 years, 26 placebo subjects and 25 duloxetine subjects) women. Women (ages 40–55 years) receiving duloxetine demonstrated significantly greater improvement in total scores on the 17-item Hamilton Rating Scale for Depression compared with placebo at the study endpoint (week 9). Significant advantages for duloxetine over placebo were observed on 17-item Hamilton depression scale subscales (core, Maier, anxiety, retardation, and sleep), in addition to the Clinical Global Impression severity and Patient Global Impression of Improvement Scale, the Quality of Life in Depression Scale, and Visual Analog Scales assessing pain severity. The magnitude of duloxetine’s treatment effect in women ages 40–55 years was similar to that observed in younger (age <40 years) and older (age >55 years) female patients. In the placebo treatment groups, however, mean changes differed substantially by age group with the smallest placebo responses observed in the 40–55 age group. Duloxetine (60 mg/day) was demonstrated to be an effective treatment for major depressive disorder in this cohort of women ages 40–55 years.

This article has been cited by other articles:

				B. Kundermann, J. Hemmeter-Spernal, M. T. Huber, J.-C. Krieg, and S. Lautenbacher Effects of Total Sleep Deprivation in Major Depression: Overnight Improvement of Mood is Accompanied by Increased Pain Sensitivity and Augmented Pain Complaints Psychosom Med, January 1, 2008; 70(1): 92 - 101. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us